Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30334729 | 1.00 | CYP1A2 (0.63) | CYP1A2CYP2C19NPSR1MAPTBAZ2B | |
| SCHEMBL12316616 | 0.88 | CYP1A2 (0.63) | CYP1A2CYP2C19NPSR1MAPTBAZ2B | |
| SCHEMBL21505562 | 0.86 | MAOB (0.54) | CYP1A2CYP2C19NPSR1MAPTBAZ2B | |
| SCHEMBL2494907 | 0.85 | AAK1 (0.60) | CYP1A2CYP2C19NPSR1MAPTBAZ2B | |
| SCHEMBL2249683 | 0.80 | CYP1A2 (0.69) | CYP1A2CYP2C19NPSR1MAPTBAZ2B | |
| SCHEMBL32670198 | 0.80 | MAOB (0.61) | NPSR1MAPTMAOAMAOBALDH1A1 | |
| SCHEMBL6207360 | 0.80 | CYP1A2 (0.60) | CYP1A2CYP2C19NPSR1MAPTBAZ2B | |
| SCHEMBL5861384 | 0.78 | CYP1A2 (1.00) | CYP1A2CYP2C19NPSR1MAPTALDH1A1 | |
| SCHEMBL2245426 | 0.77 | CYP1A2 (0.69) | CYP1A2CYP2C19NPSR1MAPTBAZ2B | |
| SCHEMBL12316629 | 0.75 | KDM4E (0.49) | CYP1A2CYP2C19NPSR1MAPTBAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| CN-116490201-A | Inhibitors of YAP/TAZ-TEAD tumor proteins, their synthesis and use | 布里奇恩生物科学公司 | 2023-07-25 | — | — | CN | disclosed |
| WO-2022006548-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| WO-1998009969-A1 | NOVEL ARYL-PYRIDAZINES | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-03-12 | — | — | WO | disclosed |
| EP-0357788-B1 | PYRIDAZINONE DERIVATIVES | NIPPON SODA CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| US-5110925-A | Cardiotonic agents | NIPPON SODA CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0357788-A1 | PYRIDAZINONE DERIVATIVES. | NIPPON SODA CO (JP) | 1990-03-14 | — | — | EP | disclosed |
| WO-1989007594-A1 | PYRIDAZINONE DERIVATIVES | NIPPON SODA CO., LTD. (JP) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | TEAD1, TEAD2, TEAD3 | CYP1A2 4117/4885CYP2C19 4316/4885NPSR1 4740/4885 |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | CYP1A2 1433/4885CYP2C19 1595/4885NPSR1 29/4885 |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | CYP1A2 2365/4885CYP2C19 1044/4885NPSR1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.